ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025
TNF-α Inhibition Modulates CX3CR1, Pyroptosis-related Genes, and BDNF to Alleviate Anxiety-like Behavior in Type 2 Diabetic Rats.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Upregulated Klotho expression reflects a potential compensatory renal response in Trimethyltin-exposed rats.Medical molecular morphology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundType 2 diabetes is strongly associated with neuroinflammation and neurodegeneration in the hippocampus, yet the underlying mechanisms are not fully understood. This study seeks to address this gap by exploring the role of TNF-α in modulating behavior, fractalkine (CX3CL1) signaling, and pyroptosis-related pathways in the hippocampus of streptozotocin (STZ)-nicotinamide (NA)-induced diabetic rats, thereby providing insights into potential therapeutic targets for diabetes-induced neuroinflammation.
methodsMale Sprague–Dawley rats (10–12 weeks old) were assigned to three groups: the etanercept-treated diabetic (DE) group, diabetic control (DC) group, and normal control (NC) group. Type 2 diabetes was induced via intraperitoneal injections of STZ and NA, with fasting blood glucose levels > 200 mg/dL confirming the condition. Etanercept was administered biweekly. Anxiety-like behavior and locomotor activity were evaluated using the open field test. After ten weeks, the rats were sacrificed, and the hippocampal tissues were dissected for immunohistochemical analysis of GFAP, CX3CR1, CX3CL1, BDNF expression, as well as qPCR, to quantify pyroptosis-related gene expression.
resultsTNF-α inhibition through etanercept treatment attenuated anxiety-like behavior, reduced GFAP and CX3CR1 expression, and lowered the levels of pyroptosis-related genes (Il-1b, Il-18, Nlrp3) in the hippocampus of diabetic rats, whereas CX3CL1 expression remained unaffected. Additionally, etanercept treatment increased BDNF expression in the hippocampus, suggesting a potential neuroprotective effect.
conclusionThis study suggests that TNF-α inhibition decreases hippocampal GFAP, CX3CR1, and pyroptosis-related gene expression, while enhancing BDNF. These changes may contribute to reduced anxiety-like behavior, highlighting a potential neuroprotective role of TNF-α inhibition in type 2 diabetes.
Indexed as
Identifiers
41075047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.